Kiniksa Pharmaceuticals Ltd - ESG Rating & Company Profile powered by AI
This analysis of Kiniksa Pharmaceuticals Ltd was assembled by All Street Sevva using advanced NLP. Complete ESG analysis of Kiniksa Pharmaceuticals Ltd are accessed by signing in. If you work at Kiniksa Pharmaceuticals Ltd and you would like to licence your ESG rating, please get in touch.
Kiniksa Pharmaceuticals Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 4.0, social score of 3.2 and governance score of 3.2.
3.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1144 | Veerhealth Care Ltd | 3.6 | Medium |
| 1144 | iStreet Network Ltd | 3.6 | Medium |
| 1186 | Kiniksa Pharmaceuticals Ltd | 3.5 | Medium |
| 1186 | CRISPR Therapeutics AG | 3.5 | Medium |
| 1186 | Catalent Inc | 3.5 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Kiniksa Pharmaceuticals Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd report the average age of the workforce?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd offer flexible work?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd conduct supply chain audits?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose water use targets?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Kiniksa Pharmaceuticals Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Kiniksa Pharmaceuticals Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Kiniksa Pharmaceuticals Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose its waste policy?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose energy use targets?
Sign up for free to unlockDoes Kiniksa Pharmaceuticals Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Kiniksa Pharmaceuticals Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Kiniksa Pharmaceuticals Ltd
These potential risks are based on the size, segment and geographies of the company.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.